Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · see citing works

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · see citing works

PD-1 and Its Ligands in Tolerance and Immunity

Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · see citing works

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · see citing works

Restoring function in exhausted CD8 T cells during chronic viral infection

Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 3,960 · see citing works

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · see citing works

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · see citing works

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,383 · see citing works

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324 · see citing works

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · see citing works

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works

EMT and Dissemination Precede Pancreatic Tumor Formation

Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136 · see citing works

Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection

Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · see citing works

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · see citing works

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085 · see citing works

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · see citing works

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · see citing works

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · see citing works

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,678 · see citing works

Up-Regulation of PD-L1, IDO, and T _regs in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells

Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · see citing works

Molecular mechanism and function of CD40/CD40L engagement in the immune system

Elgueta, R., Benson, M. J., de Vries, V. C., Wasiuk, A., Guo, Y., & Noelle, R. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00782.x · Cited by 1,633 · see citing works

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · see citing works

Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection

Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355 · see citing works

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models

Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324 · see citing works

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Royal, R. E., Levy, C. L., Turner, K. M., Mathur, A., Hughes, M. S., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C.-H., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,266 · see citing works

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,237 · see citing works

Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H., Collisson, E. A., Connor, F., Van Dyke, T., Kozlov, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.007 · Cited by 1,158 · see citing works

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120 · see citing works

Dynamics of the immune reaction to pancreatic cancer from inception to invasion

Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer

Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 4× · see citing works

Progenitor and Terminal Subsets of CD8 + T Cells Cooperate to Contain Chronic Viral Infection

Paley, M., Kroy, D. C., Odorizzi, P. M., Johnnidis, J. B., Dolfi, D. V., Barnett, B. E., Bikoff, E. K., Robertson, E. J., Lauer, G. M., Reiner, S. L., et al. (2012) · Science · doi:10.1126/science.1229620 · Cited by 903 · see citing works

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · see citing works

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 861 · see citing works

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · see citing works

Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions

Hiraoka, N., Onozato, K., Kosuge, T., & Hirohashi, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0369 · Cited by 831 · see citing works

Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma

Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777 · see citing works

An immune-active tumor microenvironment favors clinical response to ipilimumab

Ji, R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J. P., Alaparthy, S., Berman, D., Jure‐Kunkel, M., Siemers, N. O., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 771 · see citing works

Programmed death ligand-1 expression in non-small cell lung cancer

Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 752 · see citing works

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 737 · see citing works

Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia

Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 1× · see citing works

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711 · see citing works

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer

Monte, L. B. D., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H. R., Braga, M., Carlo, V. D., Doglioni, C., & Protti, M. P. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 692 · see citing works

Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade

Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801497105 · Cited by 575 · see citing works

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

Le, D. T., Lutz, E. R., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Donehower, R. C., Jaffee, E. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829fb7a2 · Cited by 566 · see citing works

Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

Lutz, E. R., Wu, A. A., Bigelow, E. O., Sharma, R. B., Mo, G., Soares, K. C., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 551 · see citing works

Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T Cell Exhaustion versus Memory

Doering, T. A., Crawford, A., Angelosanto, J., Paley, M., Ziegler, C. G. K., & Wherry, E. J. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.021 · Cited by 542 · see citing works

CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma

Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. (2003) · Pancreas · doi:10.1097/00006676-200401000-00023 · Cited by 532 · see citing works

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 529 · see citing works

Immune Modulation in Cancer with Antibodies

Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 516 · see citing works

Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection

Crawford, A., Angelosanto, J., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 495 · see citing works

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2063 · Cited by 490 · see citing works

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 414 · see citing works

PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

Soares, K. C., Rucki, A. A., Wu, A. A., Olino, K. L., Xiao, Q., Chai, Y., Wamwea, A., Bigelow, E. O., Lutz, E. R., Liu, L. L., et al. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000062 · Cited by 398 · see citing works

Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response

Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C. H. H., Joseph‐Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O. A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378 · see citing works

Systemic and local immunosuppression in pancreatic cancer patients.

von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Jöhnk, C., Henne‐Bruns, D., Kremer, B., & Kalthoff, H. (2001) · PubMed · Cited by 279 · see citing works

Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R. H., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256 · see citing works

Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy

Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250 · see citing works

Inflammatory networks and immune surveillance of pancreatic carcinoma

Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 201 · see citing works

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

Mangsbo, S. M., Sandin, L. C., Anger, K., Korman, A. J., Loskog, A., & Tötterman, T. H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181c01fcb · Cited by 198 · see citing works

Inhibitory Receptors on Lymphocytes: Insights from Infections

Odorizzi, P. M., & Wherry, E. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100038 · Cited by 168 · see citing works

Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer

Clark, C. E., Beatty, G. L., & Vonderheide, R. H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.037 · Cited by 157 · see citing works

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages

Buhtoiarov, I. N., Sondel, P. M., Wigginton, J. M., Buhtoiarova, T. N., Yanke, E. M., Mahvi, D. A., & Rakhmilevich, A. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03357.x · Cited by 143 · see citing works

Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects

Cho, H.-I., & Celis, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2019 · Cited by 142 · see citing works

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ

Ho, P.-C., Meeth, K. M., Tsui, Y.-C., Srivastava, B., Bosenberg, M. W., & Kaech, S. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3461 · Cited by 126 · see citing works

CD40 immunotherapy for pancreatic cancer

Vonderheide, R. H., Bajor, D. L., Winograd, R., Evans, R. A., Bayne, L. J., & Beatty, G. L. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1427-5 · Cited by 115 · see citing works

CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice

Zhang, Y., Yan, W., Mathew, E., Bednar, F., Wan, S., Collins, M. A., Evans, R. A., Welling, T. H., Vonderheide, R. H., & di Magliano, M. P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0016-t · Cited by 102 · see citing works

Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer

Richman, L. P., & Vonderheide, R. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0152 · Cited by 91 · see citing works

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

Sandin, L. C., Eriksson, F., Ellmark, P., Loskog, A., Tötterman, T. H., & Mangsbo, S. M. (2014) · OncoImmunology · doi:10.4161/onci.27614 · Cited by 87 · see citing works

Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization

Zhou, Q., Xiao, H., Liu, Y., Peng, Y., Yuan, H., Yagita∥, H., Chandler, P., Munn, D. H., Mellor, A. L., Fu, N., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001821 · Cited by 62 · see citing works

Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model

Williams, E. L., Dunn, S. N., James, S., Johnson, P., Cragg, M. S., Glennie, M. J., & Gray, J. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3226 · Cited by 46 · see citing works

Abstract 5513: An immune-active tumor microenvironment favors clinical response to ipilimumab

Ji, R., Hamid, O., Chasalow, S. D., Cogswell, J. P., Alaparthy, S., Berman, D., & Shahabi, V. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-5513 · Cited by 5 · see citing works

Tumour-associated macrophages as treatment targets in oncology

Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,065 · see citing works

Macrophages as regulators of tumour immunity and immunotherapy

DeNardo, D. G., & Ruffell, B. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,542 · see citing works

Pancreatic cancer: Advances and challenges

Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · see citing works

Targeting the tumour stroma to improve cancer therapy

Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084 · see citing works

Dendritic cell-based immunotherapy

Sabado, R. L., Balan, S., & Bhardwaj, N. (2016) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 926 · see citing works

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P. J., Upstill‐Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 842 · see citing works

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 738 · see citing works

De-novo and acquired resistance to immune checkpoint targeting

Syn, N. L. X., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 742 · see citing works

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674 · see citing works

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571892 · Cited by 647 · see citing works

Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer

Carstens, J. L., Correa de Sampaio, P., Yang, D., Barua, S., Wang, H., Rao, A., Allison, J. P., LeBleu, V. S., & Kalluri, R. (2017) · Nature Communications · doi:10.1038/ncomms15095 · Cited by 633 · see citing works

Tumor microenvironment participates in metastasis of pancreatic cancer

Ren, B., Cui, M., Yang, G., Wang, H., Feng, M., You, L., & Zhao, Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0858-1 · Cited by 590 · see citing works

Regulatory circuits of T cell function in cancer

Speiser, D. E., Ho, P., & Verdeil, G. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.80 · Cited by 559 · see citing works

CD40 agonist antibodies in cancer immunotherapy

Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544 · see citing works

In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer

Lizotte, P. H., Wen, A. M., Sheen, M. R., Fields, J., Rojanasopondist, P., Steinmetz, N. F., & Fiering, S. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2015.292 · Cited by 484 · see citing works

Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy

Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.173 · Cited by 472 · see citing works

Immunotherapy and Prevention of Pancreatic Cancer

Morrison, A. H., Byrne, K. T., & Vonderheide, R. H. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.04.001 · Cited by 469 · see citing works

Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer

Zhang, Y., Chandra, V., Riquelme, E. M., Dutta, P., Quesada, P. R., Rakoski, A. I., Zoltan, M. A., Arora, N., Baydogan, S., Horne, W. T., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190354 · Cited by 447 · see citing works

Therapeutic developments in pancreatic cancer

Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 427 · see citing works

Gut microbiota promotes tumor growth in mice by modulating immune response

Sethi, V., Kurtom, S., Tarique, M., Lavania, S., Malchiodi, Z., Hellmund, L., Zhang, L., Sharma, U., Giri, B., Garg, B., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.001 · Cited by 403 · see citing works

Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis

Zhang, Y., Lazarus, J., Steele, N. G., Yan, W., Lee, H.-J., Nwosu, Z. C., Halbrook, C. J., Menjivar, R. E., Kemp, S. B., Sirihorachai, V. R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0958 · Cited by 385 · see citing works

Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer

Halbrook, C. J., & Lyssiotis, C. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.006 · Cited by 394 · see citing works

Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 394 · see citing works

PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer

Diskin, B., Adam, S., Cassini, M. F., Soto, G. S., Liria, M., Aykut, B., Buttar, C., Li, E., Sundberg, B., Salas, R. D., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0620-x · Cited by 393 · see citing works

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Padrón, L. J., Maurer, D. M., O’Hara, M. H., O’Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01829-9 · Cited by 384 · see citing works

Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer

Kemp, S. B., Cheng, N., Markosyan, N., Sor, R., Kim, I.-K., Hallin, J., Shoush, J., Quinones, L., Brown, N. V., Bassett, J. B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1066 · Cited by 370 · see citing works

Stromal biology and therapy in pancreatic cancer: ready for clinical translation?

Neeße, A., Bauer, C. A., Öhlund, D., Lauth, M., Buchholz, M., Michl, P., Tuveson, D. A., & Gress, T. M. (2018) · Gut · doi:10.1136/gutjnl-2018-316451 · Cited by 348 · see citing works

Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells

Manzo, T., Prentice, B. M., Anderson, K. G., Raman, A. T., Schalck, A. P., Codreanu, G. S., Lauson, C. B. N., Tiberti, S., Raimondi, A., Jones, M. A., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191920 · Cited by 345 · see citing works

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer

Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & di Magliano, M. P. (2016) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 338 · see citing works

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

Blando, J., Sharma, A., Higa, M. G., Zhao, H., Vence, L., Yadav, S. S., Kim, J., Sepulveda, A. M., Sharp, M., Maitra, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811067116 · Cited by 334 · see citing works

Microenvironmental Determinants of Pancreatic Cancer

Heßmann, E., Buchholz, S., Demir, İ. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neeße, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 329 · see citing works

Development of Immunotherapy Combination Strategies in Cancer

Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 336 · see citing works

A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression

Auciello, F. R., Bulusu, V., Oon, C., Tait-Mulder, J., Berry, M., Bhattacharyya, S., Tumanov, S., Allen-Petersen, B. L., Link, J., Kendsersky, N. D., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1212 · Cited by 332 · see citing works

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30532-5 · Cited by 307 · see citing works

Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses

Anfray, C., Ummarino, A., Andón, F. T., & Allavena, P. (2019) · Cells · doi:10.3390/cells9010046 · Cited by 305 · see citing works

CD40 stimulation obviates innate sensors and drives T cell immunity in cancer

Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282 · see citing works

The Immune Revolution: A Case for Priming, Not Checkpoint

Vonderheide, R. H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.008 · Cited by 294 · see citing works

Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer

Chen, Y., Yang, S., Tavormina, J., Tampe, D., Zeisberg, M., Wang, H., Mahadevan, K. K., Wu, C.-J., Sugimoto, H., Chang, C.-C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.011 · Cited by 289 · see citing works

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer

Freed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.007 · Cited by 273 · see citing works

Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

Xiao, Z., Todd, L., Huang, L., Noguera-Ortega, E., Lu, Z., Huang, L., Kopp, M., Li, Y., Pattada, N., Zhong, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40850-5 · Cited by 272 · see citing works

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion

Lu, C., Paschall, A. V., Shi, H., Savage, N. M., Waller, J. L., Sabbatini, M. E., Oberlies, N. H., Pearce, C. J., & Liu, K. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw283 · Cited by 264 · see citing works

Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer

Kurz, E., Hirsch, C. A., Dalton, T., Shadaloey, S. A., Khodadadi-Jamayran, A., Miller, G., Pareek, S., Rajaei, H., Mohindroo, C., Baydogan, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.05.006 · Cited by 258 · see citing works

CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma

Chao, T., Furth, E. E., & Vonderheide, R. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0188 · Cited by 248 · see citing works

The Immune Microenvironment in Pancreatic Cancer

Huber, M., Brehm, C. U., Gress, T. M., Buchholz, M., Alhamwe, B. A., von Strandmann, E. P., Slater, E. P., Bartsch, J. W., Bauer, C. A., & Lauth, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197307 · Cited by 243 · see citing works

Genetic and Epigenetic Regulation of PD-1 Expression

Bally, A. P. R., Austin, J. W., & Boss, J. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502643 · Cited by 245 · see citing works

Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy

Jiang, H., Hegde, S., & DeNardo, D. G. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2003-1 · Cited by 243 · see citing works

Current and future immunotherapeutic approaches in pancreatic cancer treatment

Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 247 · see citing works

Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

Fan, J., Wang, M., Chen, H., Shang, D., Das, J. K., & Song, J. J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01151-3 · Cited by 228 · see citing works

Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer

Seo, Y. D., Jiang, X., Sullivan, K. M., Jalikis, F. G., Smythe, K. S., Abbasi, A., Vignali, M., Park, J. O., Daniel, S. K., Pollack, S. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0081 · Cited by 227 · see citing works

Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., & Ullenhag, G. J. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1037-z · Cited by 225 · see citing works

STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models

Jing, W., McAllister, D. M., Vonderhaar, E. P., Palen, K. A., Riese, M. J., Gershan, J. A., Johnson, B. D., & Dwinell, M. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0573-5 · Cited by 218 · see citing works

Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy

Martínez‐Bosch, N., Vinaixa, J., & Navarro, P. (2018) · Cancers · doi:10.3390/cancers10010006 · Cited by 207 · see citing works

Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model ( LSL‐Kras G12D/+ ;LSL‐Trp53 R172H/+ ;Pdx‐1‐Cre ), Its Variants, and Their Application in Immuno‐oncology Drug Discovery

Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. L., & Beatty, G. L. (2016) · Current Protocols in Pharmacology · doi:10.1002/cpph.2 · Cited by 209 · see citing works

Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer

Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt‐Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 213 · see citing works

Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment

Looi, C.-K., Chung, F. F., Leong, C., Wong, S. F., Rosli, R., & Mai, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 206 · see citing works

CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion

Günaydın, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668349 · Cited by 205 · see citing works

T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma

Stromnes, I. M., Schmitt, T. M., Hulbert, A., Brockenbrough, J. S., Nguyen, H., Cuevas, C. M., Dotson, A., Tan, X., Hotes, J. L., Greenberg, P. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.022 · Cited by 201 · see citing works

T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma

Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 201 · see citing works

Neoadjuvant Selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer

Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1047 · Cited by 199 · see citing works

TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis

Principe, D. R., DeCant, B. T., Mascariñas, E., Wayne, E. A., Diaz, A. M., Akagi, N., Hwang, R. F., Pasche, B., Dawson, D. W., Fang, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1293 · Cited by 197 · see citing works

Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model

Kuen, J., Darowski, D., Kluge, T., & Majety, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182039 · Cited by 192 · see citing works

The Pancreatic Cancer Microenvironment

Dougan, S. K. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000288 · Cited by 186 · see citing works

Lack of immunoediting in murine pancreatic cancer reversed with neoantigen

Evans, R. A., Diamond, M. S., Rech, A. J., Chao, T., Richardson, M. W., Lin, J., Bajor, D. L., Byrne, K. T., Stanger, B. Z., Riley, J. L., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88328 · Cited by 180 · see citing works

Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis

Lin, J. H., Huffman, A. P., Wattenberg, M. M., Walter, D. M., Carpenter, E. L., Feldser, D. M., Beatty, G. L., Furth, E. E., & Vonderheide, R. H. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190673 · Cited by 171 · see citing works

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

Lu, C., Talukder, A. M., Savage, N. M., Singh, N., & Liu, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1291106 · Cited by 176 · see citing works

Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)

Markosyan, N., Li, J., Sun, Y. H., Richman, L. P., Lin, J. H., Yan, F., Quinones, L., Sela, Y., Yamazoe, T., Gordon, N., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127755 · Cited by 167 · see citing works

Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes

Kim, S. I., Cassella, C. R., & Byrne, K. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.629722 · Cited by 169 · see citing works

Reprogrammed Schwann Cells Organize into Dynamic Tracks that Promote Pancreatic Cancer Invasion

Deborde, S., Gusain, L., Powers, A. E., Marcadis, A. R., Yu, Y., Chen, C.-H., Frants, A., Kao, E., Tang, L. H., Vakiani, E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1690 · Cited by 170 · see citing works

Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity

Perry, C. J., Muñoz-Rojas, A., Meeth, K., Kellman, L. N., Amezquita, R., Thakral, D., Du, V. Y., Wang, J. X., Damsky, W., Kuhlmann, A., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171435 · Cited by 121 · see citing works

Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists

Beatty, G. L., Li, Y., & Long, K. B. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1270208 · Cited by 162 · see citing works

Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development

Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 160 · see citing works

Targeting tumor-associated macrophages as an antitumor strategy

Cheng, N., Bai, X., Shu, Y., Ahmad, O., & Shen, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114354 · Cited by 162 · see citing works

Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment

Peske, J. D., Woods, A. B., & Engelhard, V. H. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.05.001 · Cited by 159 · see citing works

Immunotherapy for pancreatic cancer: Barriers and breakthroughs

Torphy, R. J., Zhu, Y., & Schulick, R. D. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12176 · Cited by 150 · see citing works

Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus

Eriksson, E., Milenova, I. E., Wenthe, J., Ståhle, M., Leja-Jarblad, J., Ullenhag, G. J., Dimberg, A., Moreno, R., Alemany, R., & Loskog, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0285 · Cited by 151 · see citing works

Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity

Morrison, A. H., Diamond, M. S., Hay, C. A., Byrne, K. T., & Vonderheide, R. H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918971117 · Cited by 149 · see citing works

The role of histone methylation in the development of digestive cancers: a potential direction for cancer management

Chen, Y., Ren, B., Yang, J., Wang, H., Yang, G., Xu, R., You, L., & Zhao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00252-1 · Cited by 143 · see citing works

Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment

Foucher, E. D., Ghigo, C., Chouaı̈b, S., Galon, J., Iovanna, J., & Olive, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01044 · Cited by 139 · see citing works

Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers

Shen, L., Li, J., Liu, Q., Song, W., Zhang, X., Tiruthani, K., Hu, H., Das, M., Goodwin, T. J., Liu, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00967 · Cited by 138 · see citing works

Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer

Li, J., Yuan, S., Norgard, R. J., Yan, F., Sun, Y. H., Kim, I., Merrell, A. J., Sela, Y., Jiang, Y., Bhanu, N. V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0519 · Cited by 132 · see citing works

Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer

Leal, A. S., Williams, C. R., Royce, D. B., Pioli, P. A., Sporn, M. B., & Liby, K. T. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.021 · Cited by 134 · see citing works

Inflammatory Monocytes Promote Perineural Invasion via CCL2-Mediated Recruitment and Cathepsin B Expression

Bakst, R. L., Xiong, H., Chen, C., Deborde, S., Lyubchik, A., Zhou, Y., He, S., McNamara, W. A., Lee, S., Olson, O. C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1612 · Cited by 132 · see citing works

Viscoelastic properties of human pancreatic tumors and in vitro constructs to mimic mechanical properties

Rubiano, A. M., Delitto, D., Han, S., Gerber, M. H., Galitz, C., Trevino, J. G., Thomas, R. M., Hughes, S. J., & Simmons, C. S. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.11.037 · Cited by 132 · see citing works

Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer

Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C. M., Goodwin, T. J., Dorosheva, O., Liu, R., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01786 · Cited by 131 · see citing works

TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer

Principe, D. R., Park, A. J., Dorman, M. J., Kumar, S., Viswakarma, N., Rubin, J., Torres, C., McKinney, R. D., Munshi, H. G., Grippo, P. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0850 · Cited by 126 · see citing works

A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity

Ma, H. S., Poudel, B., Torres, E. T. R., Sidhom, J.-W., Robinson, T. M., Christmas, B. J., Scott, B., Cruz, K. A., Woolman, S., Wall, V., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0061 · Cited by 124 · see citing works

Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy

Principe, D. R., Narbutis, M., Kumar, S., Park, A. J., Viswakarma, N., Dorman, M. J., Kamath, S. D., Grippo, P. J., Fishel, M. L., Hwang, R. F., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2959 · Cited by 123 · see citing works

T-cell agonists in cancer immunotherapy

Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000966 · Cited by 119 · see citing works

CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity

Huffman, A. P., Lin, J. H., Kim, S. I., Byrne, K. T., & Vonderheide, R. H. (2020) · JCI Insight · doi:10.1172/jci.insight.137263 · Cited by 122 · see citing works

Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer

Totiger, T. M., Srinivasan, S., Jala, V. R., Lamichhane, P., Dosch, A. R., Gaidarski, A. A., Joshi, C. G., Rangappa, S., Castellanos, J. A., Vemula, P. K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0464 · Cited by 121 · see citing works

OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway

Pang, X., Wang, S., Zhang, M., Jiang, J. D., Fan, H., Wu, J., Wang, H., Liang, X., & Tang, Y. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02741-2 · Cited by 121 · see citing works

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

Bajor, D. L., Mick, R., Riese, M. J., Huang, A. C., Sullivan, B. J., Richman, L. P., Torigian, D. A., George, S. M., Stelekati, E., Chen, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1468956 · Cited by 119 · see citing works

CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer

Huang, J., Chen, P., Liu, K., Liu, J., Zhou, B., Wu, R., Qiu, P., Liu, Z., Li, C., Kroemer, G., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320441 · Cited by 120 · see citing works

Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent

Pantziarka, P., Sukhatme, V. V., Bouche, G., Melhuis, L., & Sukhatme, V. P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.610 · Cited by 118 · see citing works

Targeting Innate Immunity in Cancer Therapy

Rameshbabu, S., Labadie, B. W., Argulian, A., & Patnaik, A. (2021) · Vaccines · doi:10.3390/vaccines9020138 · Cited by 118 · see citing works

B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer

Mirlekar, B., Michaud, D. E., Lee, S. J., Kren, N. P., Harris, C., Greene, K. G., Goldman, E. C., Gupta, G. P., Fields, R. C., Hawkins, W. G., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0349 · Cited by 118 · see citing works

3D approaches to model the tumor microenvironment of pancreatic cancer

Bort, E. T., Kieler, M., Sharma, S., Candido, J. B., & Loessner, D. (2020) · Theranostics · doi:10.7150/thno.42441 · Cited by 117 · see citing works

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes

Federico, A. D., Mosca, M., Pagani, R., Carloni, R., Frega, G., Giglio, A. D., Rizzo, A., Ricci, D., Tavolari, S., Marco, M. D., et al. (2022) · Cancers · doi:10.3390/cancers14102429 · Cited by 115 · see citing works

Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer

Rech, A. J., Dada, H., Kotzin, J. J., Henao‐Mejia, J., Minn, A. J., Victor, C. T.-S., & Vonderheide, R. H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3821 · Cited by 116 · see citing works

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models

Sow, H. S., Ren, J., Camps, M. G. M., OSSENDORP, F. A., & ten Dijke, P. (2019) · Cells · doi:10.3390/cells8040320 · Cited by 112 · see citing works

Induction of T cell immunity overcomes resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic cancer

Winograd, R. (2015) · ScholarlyCommons (University of Pennsylvania)

Abstract IA05: Breaking immune privilege in pancreatic cancer

Vonderheide, R. H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6074.tumimm14-ia05

Abstract 4940: Nonredundant roles for immune checkpoint blockade and agonistic CD40 in mediating T-cell responses in pancreatic ductal adenocarcinoma

Morrison, A. H., Byrne, K. T., & Vonderheide, R. H. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-4940

Abstract 2985: Radiotherapy and αCD40 non-redundantly augment immunity to checkpoint blockade in refractory pancreatic ductal adenocarcinoma

Dada, H., Rech, A. J., Victor, C. T.-S., Minn, A. J., & Vonderheide, R. H. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2985

Abstract PR4: Restoring T cell immuno-surveillance in pancreatic carcinoma using CD40 agonists.

Beatty, G. L., Winograd, R., Evans, R. A., Luque, S. L., Guirnalda, P. D., & Vonderheide, R. H. (2013) · Cancer Research · doi:10.1158/1538-7445.tumimm2012-pr4